دورية أكاديمية
أعرض في EDS

Single-cell RNA sequencing uncovers heterogeneous transcriptional signatures in tumor-infiltrated dendritic cells in prostate cancer.

التفاصيل البيبلوغرافية
العنوان: Single-cell RNA sequencing uncovers heterogeneous transcriptional signatures in tumor-infiltrated dendritic cells in prostate cancer.
المؤلفون: Feriz AM; Birjand University of Medical Sciences (BUMS), Birjand, Iran.; Cellular and Molecular Research Center, BUMS, Birjand, Iran., Khosrojerdi A; Cellular and Molecular Research Center, BUMS, Birjand, Iran., Lotfollahi M; Computational Health Center, Helmholtz Munich, Germany.; Wellcome Sanger Institute, Cambridge, UK., Shamsaki N; Birjand University of Medical Sciences (BUMS), Birjand, Iran., GhasemiGol M; College of Engineering & Mines, University of North Dakota, North Dakota, USA., HosseiniGol E; Department of Computer Engineering, University of Birjand, Birjand, Iran., Fereidouni M; Cellular and Molecular Research Center, BUMS, Birjand, Iran., Rohban MH; Department of Computer Engineering, Sharif University of Technology, Tehran, Iran., Sebzari AR; Radiation Oncology, Clinical Research Development Unit (CRDU), ValiAsr Hospital, BUMS, Birjand, Iran., Saghafi S; Birjand University of Medical Sciences (BUMS), Birjand, Iran., Leone P; Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy., Silvestris N; Medical Oncology Unit, Department of Human Pathology 'G. Barresi', University of Messina, Messina, Italy., Safarpour H; Cellular and Molecular Research Center, BUMS, Birjand, Iran., Racanelli V; Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy.
المصدر: Heliyon [Heliyon] 2023 Apr 23; Vol. 9 (5), pp. e15694. Date of Electronic Publication: 2023 Apr 23 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: eCollection Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : Elsevier Ltd, [2015]-
مستخلص: Prostate cancer (PCa) is one of the two solid malignancies in which a higher T cell infiltration in the tumor microenvironment (TME) corresponds with a worse prognosis for the tumor. The inability of T cells to eliminate tumor cells despite an increase in their number reinforces the possibility of impaired antigen presentation. In this study, we investigated the TME at single-cell resolution to understand the molecular function and communication of dendritic cells (DCs) (as professional antigen-presenting cells). According to our data, tumor cells stimulate the migration of immature DCs to the tumor site by inducing inflammatory chemokines. Many signaling pathways such as TNF-α/NF-κB, IL2/STAT5, and E2F up-regulated after DCs enter the tumor location. In addition, some molecules such as GPR34 and SLCO2B1 decreased on the surface of DCs. The analysis of molecular and signaling alterations in DCs revealed some suppression mechanisms of tumors, such as removing mature DCs, reducing the DC's survival, inducing anergy or exhaustion in the effector T cells, and enhancing the differentiation of T cells to Th2 and T regs . In addition, we investigated the cellular and molecular communication between DCs and macrophages in the tumor site and found three molecular pairs including CCR5 / CCL5 , CD52 / SIGLEC10 , and HLA - DPB1 / TNFSF13B . These molecular pairs are involved in the migration of immature DCs to the TME and disrupt the antigen-presenting function of DCs. Furthermore, we presented new therapeutic targets by the construction of a gene co-expression network. These data increase our knowledge of the heterogeneity and the role of DCs in PCa TME.
Competing Interests: The authors declare no conflict of interest.
(© 2023 The Authors. Published by Elsevier Ltd.)
References: Drug Des Devel Ther. 2015 Oct 01;9:5447-68. (PMID: 26491256)
Genes Dis. 2022 Jan;9(1):12-27. (PMID: 34514075)
Exp Dermatol. 2008 Sep;17(9):739-47. (PMID: 18557925)
Nat Biotechnol. 2018 Dec 03;:. (PMID: 30531897)
J Immunol. 2005 Jun 1;174(11):7154-9. (PMID: 15905559)
Cancers (Basel). 2021 May 02;13(9):. (PMID: 34063238)
Cancer Metastasis Rev. 2006 Sep;25(3):409-16. (PMID: 16951987)
Cell. 2010 Mar 19;140(6):883-99. (PMID: 20303878)
Front Oncol. 2022 Apr 05;12:784183. (PMID: 35449575)
NAR Genom Bioinform. 2020 Sep;2(3):lqaa078. (PMID: 33015620)
J Immunol. 2016 Mar 15;196(6):2504-13. (PMID: 26851221)
J Transl Med. 2022 Nov 12;20(1):527. (PMID: 36371231)
BMB Rep. 2021 Jan;54(1):31-43. (PMID: 33298246)
PLoS One. 2012;7(9):e45279. (PMID: 23049782)
World J Oncol. 2019 Apr;10(2):63-89. (PMID: 31068988)
Front Immunol. 2020 Feb 14;11:124. (PMID: 32117274)
Am Fam Physician. 2018 Jun 15;97(12):798-805. (PMID: 30216009)
Mod Pathol. 2018 Jan;31(S1):S110-121. (PMID: 29297495)
J Exp Med. 2022 Feb 7;219(2):. (PMID: 34919143)
Front Immunol. 2021 Oct 12;12:713757. (PMID: 34712225)
J Clin Oncol. 2020 Feb 10;38(5):395-405. (PMID: 31774688)
Nucleic Acids Res. 2021 Jan 8;49(D1):D1144-D1151. (PMID: 33237278)
J Natl Compr Canc Netw. 2018 May;16(5S):594-596. (PMID: 29784734)
J Immunol. 2003 Apr 15;170(8):4201-8. (PMID: 12682253)
Clin Exp Med. 2022 Sep 29;:. (PMID: 36173487)
Nat Methods. 2022 Feb;19(2):171-178. (PMID: 35102346)
Nat Rev Urol. 2021 Sep;18(9):556-571. (PMID: 34239139)
J Cancer. 2017 Feb 25;8(5):761-773. (PMID: 28382138)
Stem Cell Res Ther. 2021 Jan 25;12(1):81. (PMID: 33494834)
Science. 2017 Apr 21;356(6335):. (PMID: 28428369)
Cancer. 2017 Dec 15;123 Suppl 24:5160-5177. (PMID: 29205313)
Genome Biol. 2018 Feb 6;19(1):15. (PMID: 29409532)
Ann Oncol. 2018 Aug 1;29(8):1807-1813. (PMID: 29992241)
Prostate Cancer Prostatic Dis. 2019 May;22(2):185-194. (PMID: 30131606)
Front Immunol. 2019 Mar 28;10:603. (PMID: 30984182)
J Immunol. 2010 Jun 1;184(11):6084-91. (PMID: 20421650)
J Immunother Cancer. 2019 Nov 15;7(1):306. (PMID: 31730012)
Dalton Trans. 2018 May 15;47(19):6645-6653. (PMID: 29632935)
J Cancer. 2013;4(1):36-44. (PMID: 23386903)
Immunol Cell Biol. 2002 Oct;80(5):497-505. (PMID: 12225387)
Bioinformatics. 2023 Jan 1;39(1):. (PMID: 36394263)
Eur J Immunol. 2015 May;45(5):1494-9. (PMID: 25652593)
Nat Methods. 2018 Apr;15(4):255-261. (PMID: 29481549)
Front Immunol. 2021 Sep 09;12:711329. (PMID: 34566965)
Genome Res. 2015 Dec;25(12):1860-72. (PMID: 26430063)
Int J Mol Sci. 2019 May 15;20(10):. (PMID: 31096713)
Curr Opin Immunol. 2017 Apr;45:43-51. (PMID: 28192720)
J Clin Med. 2019 Feb 06;8(2):. (PMID: 30736371)
J Clin Oncol. 2017 Jan;35(1):40-47. (PMID: 28034081)
Ther Adv Urol. 2020 Sep 3;12:1756287220951404. (PMID: 32952615)
Front Cell Dev Biol. 2022 Mar 03;10:828916. (PMID: 35309936)
Prostate. 2021 Jan;81(1):20-28. (PMID: 33085799)
Cancers (Basel). 2020 Jul 02;12(7):. (PMID: 32630699)
Bioengineered. 2020 Dec;11(1):661-678. (PMID: 32434423)
Cell Signal. 2004 Nov;16(11):1201-10. (PMID: 15337520)
JAMA Netw Open. 2019 Feb 1;2(2):e188006. (PMID: 30735235)
Science. 2016 Apr 8;352(6282):189-96. (PMID: 27124452)
Tumour Biol. 2016 Sep;37(9):11553-11572. (PMID: 27260630)
J Pharmacol Pharmacother. 2011 Oct;2(4):317-9. (PMID: 22025872)
Curr Opin Urol. 2018 Jan;28(1):15-24. (PMID: 29095729)
Cancers (Basel). 2021 Mar 10;13(6):. (PMID: 33801815)
Biomed Pharmacother. 2022 Apr;148:112725. (PMID: 35183994)
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (PMID: 29126136)
Nat Protoc. 2020 Apr;15(4):1484-1506. (PMID: 32103204)
فهرسة مساهمة: Keywords: Dendritic cells; Immunotherapy; Prostate cancer; Single-cell RNA sequencing; Tumor microenvironment
تواريخ الأحداث: Date Created: 20230505 Latest Revision: 20230507
رمز التحديث: 20230507
مُعرف محوري في PubMed: PMC10151421
DOI: 10.1016/j.heliyon.2023.e15694
PMID: 37144199
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-8440
DOI:10.1016/j.heliyon.2023.e15694